LitAlert ~~

    • Radiosensitizing Pancreatic Cancer with PARP Inhibitor and Gemcitabine: An In Vivo and a Whole-Transcriptome Analysis after Proton or Photon Irradiation.
    • Waissi W, Nicol A, Jung M, Rousseau M, Jarnet D, Noel G, Burckel H.
    • Cancers (Basel). 2021 Jan 30;13(3):E527. doi: 10.3390/cancers13030527.
    • Analysis of Italian BRCA1/2 Pathogenic Variants Identifies a Private Spectrum in the Population from the Bergamo Province in Northern Italy.
    • Figlioli G, De Nicolo A, Catucci I, Manoukian S, Peissel B, Azzollini J, Beltrami B, Bonanni B, Calvello M, Bondavalli D, Pasini B, Vignolo Lutati F, Ogliara P, Zuradelli M, Pensotti V, De Vecchi G, Volorio S, Verderio P, Pizzamiglio S, Matullo G, Aneli S, Birolo G, Zanardi F, Tondini C, Zambelli A, Livraghi L, Franchi M, Radice P, Peterlongo P.
    • Cancers (Basel). 2021 Jan 30;13(3):E532. doi: 10.3390/cancers13030532.
    • DNA damage response alterations in gastric cancer: knocking down a new wall.
    • Ricci AD, Rizzo A, Brandi G.
    • Future Oncol. 2021 Jan 29. doi: 10.2217/fon-2020-0989. Epub ahead of print.
    • Editorial
    • Concurrent germline BRCA1, BRCA2, and CHEK2 pathogenic variants in hereditary breast cancer: a case series.
    • Sukumar J, Kassem M, Agnese D, Pilarski R, Ramaswamy B, Sweet K, Sardesai S.
    • Breast Cancer Res Treat. 2021 Jan 28. doi: 10.1007/s10549-021-06095-w. Epub ahead of print.
    • Germline pathogenic variants in the Ataxia Telangiectasia Mutated (ATM) gene are associated with high and moderate risks for multiple cancers.
    • Hall MJ, Bernhisel R, Hughes E, Larson K, Rosenthal ET, Singh NA, Lancaster JM, Kurian AW.
    • Cancer Prev Res (Phila). 2021 Jan 28:canprevres.0448.2020. doi: 10.1158/1940-6207.CAPR-20-0448. Epub ahead of print.
    • Study: Breastfeeding may lower risk of ovarian cancer in women with BRCA mutations.
    • [No author given]
    • FORCE. XRAY. 2021 Jan 28.

    Original research:

    Hereditary Ovarian Cancer Clinical Study Group. Breastfeeding and the risk of epithelial ovarian cancer among women with a BRCA1 or BRCA2 mutation.

    • Investigating the causal role of MRE11A p.E506* in breast and ovarian cancer.
    • Elkholi IE, Di Iorio M, Fahiminiya S, Arcand SL, Han H, Nogué C, Behl S, Hamel N, Giroux S, de Ladurantaye M, Aleynikova O, Gotlieb WH, Côté JF, Rousseau F, Tonin PN, Provencher D, MesMasson AM, Akbari MR, Rivera B, Foulkes WD.
    • Sci Rep. 2021 Jan 28;11(1):2409. doi: 10.1038/s41598-021-81106-w.